Herpes simplex virus reaches the spinal fluid by traveling along nerve fibers from an infection site on the skin or mucous membranes. The virus doesn’t need to enter the bloodstream to get there. Instead, it hijacks the transport system inside nerve cells, riding along tiny internal tracks called microtubules until it reaches the spinal cord and brain. This can happen during a first outbreak or years later when a dormant virus reactivates.
How the Virus Travels Along Nerves
When herpes simplex virus (HSV) infects skin or mucosal tissue, it enters the nerve endings embedded in that tissue. Once inside a nerve cell, the virus attaches to a molecular motor protein that normally carries cargo toward the cell body. This motor protein pulls the virus along microtubules, which function like railroad tracks running the length of the nerve fiber, in a process called retrograde axonal transport.
The journey can cover a surprising distance. A nerve fiber from the lip or genitals may stretch many centimeters before reaching the cluster of nerve cell bodies near the spinal cord (called a ganglion). Once there, the virus deposits its genetic material into the nerve cell’s nucleus. In most cases, the virus goes dormant at this point and causes no further problems. But in a small fraction of people, the virus continues past the ganglion and enters the central nervous system, where it can infect the membranes surrounding the spinal cord and brain or the brain tissue itself. When that happens, viral particles and the immune response they trigger show up in the cerebrospinal fluid.
Primary Infection vs. Reactivation
Herpes can reach the spinal fluid during either a first infection or a later reactivation. During a primary infection, the immune system has no existing defenses against the virus, which may give it a wider window to spread into the central nervous system. During reactivation, the virus is already sitting in nerve cell bodies near the spinal cord, so it has a shorter path to travel.
There is no single pattern. Some people develop neurological symptoms during their very first herpes outbreak, while others have carried the virus for years before it causes any central nervous system involvement. In immunocompromised individuals, reactivation poses a higher risk because the immune system is less able to contain the virus at the ganglion.
HSV-1 vs. HSV-2 in the Spinal Fluid
The two types of herpes simplex virus tend to cause different problems when they reach the central nervous system. HSV-1 is the major cause of herpes encephalitis, a serious infection of the brain itself. In one study comparing the two types, about 62% of adults with HSV-1 in their spinal fluid had encephalitis, and nearly 43% of them developed lasting neurological problems.
HSV-2, by contrast, is the predominant cause of viral meningitis in adults, an infection of the membranes surrounding the brain and spinal cord rather than the brain tissue. About 84% of adults with HSV-2 in their spinal fluid had meningitis rather than encephalitis. HSV-2 meningitis is generally less dangerous, with only about 8% of patients developing neurological aftereffects. It does, however, have a notable tendency to come back.
Recurrent Herpes Meningitis
Some people experience repeated episodes of herpes meningitis, a condition called Mollaret meningitis. It is defined as at least three separate episodes with documented viral identification. Episodes are typically separated by weeks, months, or even years, and each one resolves on its own. HSV-2 is the usual cause.
The disease course varies widely. Some people have only three episodes over their lifetime, while others have reported more than 20. Most people experience three to five episodes before the condition stops recurring permanently. Each episode brings headache, fever, neck stiffness, and sensitivity to light, but the symptoms clear without lasting damage in the large majority of cases.
Symptoms That Signal CNS Involvement
When herpes reaches the spinal fluid, symptoms go well beyond the typical cold sore or genital outbreak. Meningitis causes severe headache, fever, neck stiffness, and sometimes nausea or vomiting. Encephalitis produces a more alarming set of symptoms: confusion, personality or behavior changes, seizures, difficulty with language, extreme lethargy, or a declining level of consciousness. These symptoms can develop over hours to days and represent a medical emergency.
HSV encephalitis has an estimated annual incidence of about 4.6 cases per million people, with a 30-day mortality rate around 8.3% even with treatment. It accounts for roughly 12% of all viral encephalitis cases, with the highest rates reported in North America and Europe.
How It Is Diagnosed
Detecting herpes in spinal fluid requires a lumbar puncture (spinal tap), in which a small amount of cerebrospinal fluid is drawn from the lower back. The gold standard test is a PCR assay, which searches for herpes DNA in the fluid. This test is 98% sensitive and 94% specific, meaning it catches nearly all true infections and rarely gives a false positive.
False negatives can occur, particularly if the lumbar puncture is performed very early in the illness, before enough viral DNA has accumulated in the fluid. In rare cases, patients with confirmed herpes encephalitis have had two consecutive negative PCR results before eventually testing positive. If clinical suspicion remains high, repeat testing or brain imaging may be necessary.
What Treatment Looks Like
Herpes encephalitis is treated with intravenous antiviral medication in the hospital, typically for 21 days. Early treatment dramatically improves outcomes, which is why doctors often start antiviral therapy before PCR results come back if they suspect herpes encephalitis. The goal is to stop the virus from replicating and limit damage to brain tissue.
Herpes meningitis often resolves without specific antiviral treatment, though antivirals may be used to shorten the episode or reduce severity. For people with Mollaret meningitis who experience frequent recurrences, long-term suppressive antiviral therapy is sometimes prescribed to reduce the frequency of episodes, though evidence on its effectiveness for this specific use is limited.